BR112015012854B1 - Método para purificar proteínas selecionadas do grupo consistindo em plasminogênio, ativador do plasminogênio tecidual e outra(s) protease(s), solução compreendendo fibrinogênio e/ou fator viii e/ou vwf, seu uso e formulação farmacêutica - Google Patents

Método para purificar proteínas selecionadas do grupo consistindo em plasminogênio, ativador do plasminogênio tecidual e outra(s) protease(s), solução compreendendo fibrinogênio e/ou fator viii e/ou vwf, seu uso e formulação farmacêutica Download PDF

Info

Publication number
BR112015012854B1
BR112015012854B1 BR112015012854-8A BR112015012854A BR112015012854B1 BR 112015012854 B1 BR112015012854 B1 BR 112015012854B1 BR 112015012854 A BR112015012854 A BR 112015012854A BR 112015012854 B1 BR112015012854 B1 BR 112015012854B1
Authority
BR
Brazil
Prior art keywords
fibrinogen
solution
resin
vwf
factor viii
Prior art date
Application number
BR112015012854-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015012854A2 (pt
Inventor
Hung Pham
Jeffrey Michael Hey
Darren NGUY
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of BR112015012854A2 publication Critical patent/BR112015012854A2/pt
Publication of BR112015012854B1 publication Critical patent/BR112015012854B1/pt

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112015012854-8A 2012-12-05 2013-12-05 Método para purificar proteínas selecionadas do grupo consistindo em plasminogênio, ativador do plasminogênio tecidual e outra(s) protease(s), solução compreendendo fibrinogênio e/ou fator viii e/ou vwf, seu uso e formulação farmacêutica BR112015012854B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261733761P 2012-12-05 2012-12-05
US61/733,761 2012-12-05
EP13153898.5 2013-02-04
EP13153898 2013-02-04
US13/803,740 US20140154233A1 (en) 2012-12-05 2013-03-14 Method of purifying therapeutic proteins
US13/803,740 2013-03-14
AU2013203357A AU2013203357B2 (en) 2012-12-05 2013-04-10 A method of purifying therapeutic proteins
AU2013203357 2013-04-10
PCT/AU2013/001414 WO2014085861A1 (en) 2012-12-05 2013-12-05 A method of purifying therapeutic proteins

Publications (2)

Publication Number Publication Date
BR112015012854A2 BR112015012854A2 (pt) 2017-07-11
BR112015012854B1 true BR112015012854B1 (pt) 2021-11-30

Family

ID=47630209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012854-8A BR112015012854B1 (pt) 2012-12-05 2013-12-05 Método para purificar proteínas selecionadas do grupo consistindo em plasminogênio, ativador do plasminogênio tecidual e outra(s) protease(s), solução compreendendo fibrinogênio e/ou fator viii e/ou vwf, seu uso e formulação farmacêutica

Country Status (12)

Country Link
US (5) US20140154233A1 (enExample)
EP (2) EP3483173A1 (enExample)
JP (3) JP6411360B2 (enExample)
KR (2) KR102403847B1 (enExample)
CN (2) CN109125714B (enExample)
AU (2) AU2013203357B2 (enExample)
BR (1) BR112015012854B1 (enExample)
CA (2) CA3185085A1 (enExample)
PL (1) PL2928905T3 (enExample)
RU (1) RU2685956C2 (enExample)
SG (2) SG10201704484QA (enExample)
WO (1) WO2014085861A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825555B1 (en) 2012-03-13 2017-07-12 Octapharma AG Mproved process for production of fibrinogen and fibrinogen produced thereby
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
EP3400029B1 (en) * 2016-01-07 2022-03-02 Eio Biomedical Ltd Compositions for reducing tissue adhesions
CA3029075A1 (fr) 2016-07-06 2018-01-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Fibrinogene liquide stable
WO2018042438A2 (en) 2016-09-01 2018-03-08 Plas-Free Ltd Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
KR20200038309A (ko) * 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
CN109078628B (zh) * 2018-08-27 2021-06-11 西北大学 一种以苄胺为配基的高效疏水相互作用色谱介质、制备方法及其在蛋白质复性与纯化的应用
FR3090321B1 (fr) * 2018-12-21 2023-07-14 Lab Francais Du Fractionnement Procédé de filtration du fibrinogène
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
US20240189398A1 (en) 2021-04-13 2024-06-13 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
CN115181178B (zh) * 2021-09-04 2024-04-26 广东双林生物制药有限公司 一种从冷沉淀中制备人纤维蛋白原的方法
CN118401262A (zh) 2021-12-30 2024-07-26 巴克斯特国际公司 用于纤维蛋白密封剂的纤维蛋白原和凝血酶溶液以及纤维蛋白密封剂试剂盒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
JP2887329B2 (ja) * 1991-09-05 1999-04-26 バクスター インターナショナル インク 局所用フィブリノーゲン複合体
FR2686883B1 (fr) * 1992-02-04 1994-05-13 Aquitaine Develop Transf Sanguin Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant.
WO1996002571A1 (fr) 1994-07-14 1996-02-01 Croix-Rouge De Belgique Concentre de fibrinogene issu de plasma sanguin, procede et installation pour sa preparation
EP0778884A1 (en) * 1994-09-02 1997-06-18 New York Blood Center, Inc. Production and secretion of recombinant fibrinogen by yeast
US6037457A (en) * 1997-01-31 2000-03-14 The University Of North Carolina At Chapel Hill Method for recombinant fibrinogen production
FR2772381B1 (fr) 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
DK1115745T3 (da) * 1998-09-24 2006-10-02 Pharming Intellectual Pty Bv Oprensning af fibrinogen fra væsker ved udfældning og hydrofob interaktionskromatografi
WO2001048016A1 (en) * 1999-12-23 2001-07-05 Csl Limited Separation of fibrinogen from plasma proteases
AU5441101A (en) 1999-12-23 2001-07-03 Rodger H. Rast System and method for providing individualized dosing
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
KR100871454B1 (ko) * 2001-05-21 2008-12-03 옴릭스 바이오파머슈티컬즈 에스. 에이. 단백질 용액으로부터 플라스민(오겐)의 제거
AUPR638801A0 (en) 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
US20030091558A1 (en) * 2001-10-03 2003-05-15 Woolverton Christopher J. Storage-stable fibrinogen solutions
EP1442048A2 (en) * 2001-10-30 2004-08-04 Novozymes A/S High throughput isolation of proteins by charge induction chromatography
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
JP4319979B2 (ja) * 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE10246125A1 (de) 2002-10-01 2004-04-15 Aventis Behring Gmbh Konzentrat eines Faktor VIII:C-haltigen von-Willebrand-Faktors und das dazu gehörige Verfahren
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
DE102004009400A1 (de) * 2004-02-24 2005-09-08 Zlb Behring Gmbh Fibrinogen Reinigung
CA2583081A1 (en) * 2004-06-16 2006-01-19 Bio-Rad Laboratories, Inc. Multichemistry fractionation
DK2102335T3 (da) * 2007-01-04 2012-05-07 Crucell Holland Bv Rensning af faktor XI
EP2167526B1 (en) 2007-07-11 2011-03-30 Novo Nordisk A/S Purification of factor viii using a mixed-mode or multimodal resin
EP2027875A1 (en) 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
CA2711375C (en) 2008-01-18 2019-04-16 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
CA2785594C (en) * 2010-01-08 2018-04-17 Profibrix Bv Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
CN106046147B (zh) * 2010-09-20 2019-11-19 欧克塔医药公司 纤维蛋白原生产方法
SG191071A1 (en) * 2010-12-08 2013-07-31 Amgen Inc Ion exchange chromatography in the presence of an amino acid
EP2825555B1 (en) 2012-03-13 2017-07-12 Octapharma AG Mproved process for production of fibrinogen and fibrinogen produced thereby
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins

Also Published As

Publication number Publication date
US20140154233A1 (en) 2014-06-05
AU2013203357B2 (en) 2015-08-27
EP2928905A4 (en) 2016-06-08
US20210283530A1 (en) 2021-09-16
CN109125714B (zh) 2022-08-02
CA2893373A1 (en) 2014-06-12
US9598461B2 (en) 2017-03-21
AU2013203357A1 (en) 2014-06-19
CN104981476B (zh) 2018-10-09
KR102240978B1 (ko) 2021-04-19
JP7774384B2 (ja) 2025-11-21
US20150158906A1 (en) 2015-06-11
US11426680B2 (en) 2022-08-30
WO2014085861A1 (en) 2014-06-12
EP2928905A1 (en) 2015-10-14
JP6836562B2 (ja) 2021-03-03
JP2021073280A (ja) 2021-05-13
CA3185085A1 (en) 2014-06-12
AU2013354899A1 (en) 2015-07-16
BR112015012854A2 (pt) 2017-07-11
JP6411360B2 (ja) 2018-10-24
JP2019011346A (ja) 2019-01-24
PL2928905T3 (pl) 2019-05-31
US20170143805A1 (en) 2017-05-25
HK1214833A1 (en) 2016-08-05
SG11201504372UA (en) 2015-07-30
SG10201704484QA (en) 2017-07-28
RU2015126551A (ru) 2017-01-10
JP2016501878A (ja) 2016-01-21
CN109125714A (zh) 2019-01-04
KR20150090252A (ko) 2015-08-05
RU2685956C2 (ru) 2019-04-23
EP2928905B1 (en) 2018-11-21
EP3483173A1 (en) 2019-05-15
KR102403847B1 (ko) 2022-05-31
KR20210042422A (ko) 2021-04-19
CN104981476A (zh) 2015-10-14
US20190209948A1 (en) 2019-07-11
AU2013354899B2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
JP7774384B2 (ja) 治療タンパク質の精製方法
AU2003244850B2 (en) Processes for the preparation of fibrinogen
ES2642383T3 (es) Procedimiento mejorado de producción de fibrinógeno y fibrinógeno producido por el mismo
ES2262340T3 (es) Purificacion del fibrinogeno de la leche mediante el uso de cromatografia de intercambio cationico.
US10188965B2 (en) Hydrophobic charge induction chromatographic depletion of a protein from a solution
ES2711455T3 (es) Un método de purificación de proteínas terapéuticas
HK40007788A (en) Separation of fibrinogen, fviii and/or vwf from plasma proteases by hcic
CN116322920A (zh) 使用氧化硅吸附从血浆中纯化fviii
HK1214833B (en) A method of purifying therapeutic proteins
RU2445974C2 (ru) Способ получения концентрата фактора viii из плазмы крови человека
RU2559576C1 (ru) Способ получения вирусбезопасного полного протромбинового комплекса

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2013, OBSERVADAS AS CONDICOES LEGAIS.